Mazanti-Andersen advises Ascendis Pharma as it closes its USD 460 million public offering of American Depositary Shares

Ascendis Pharma A/S, a biopharmaceutical company that utilises its innovative TransCon™ technologies to address unmet medical needs, has completed its underwritten public offering of 2,875,000 American Depositary Shares (ADS), each of which represents one ordinary share in Ascendis, at a price to the public of USD 160.00. The public offering generated gross proceeds of approximately USD 460 million.

Ascendis intends to use the net proceeds of the offering to support the commercial preparations, launch and commercial activities, clinical development and regulatory approval for lonapegsomatropin-tcgd, to fund clinical development of its other endocrinology rare disease programs, including palopegteriparatide and TransCon CNP, to identify and progress development of new product candidates, including in the therapeutic area of oncology, and for working capital and other general corporate purposes.

Mazanti-Andersen and Latham & Watkins acted as Danish and US legal counsel, respectively, for Ascendis in connection with the offering. J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Evercore Group L.L.C and SVB Leerink LLC acted as joint book-running managers for the offering.

About Ascendis
Ascendis is a biopharmaceutical company applying its innovative TransCon technologies to address unmet medical needs. Ascendis has a pipeline of three endocrinology rare disease product candidates in clinical development, including TransCon hGH for which the company recently obtained regulatory approval with the U.S. Food and Drug Administration. In addition to its clinical pipeline in endocrinology rare diseases, Ascendis has multiple preclinical programs in oncology as its second therapeutic area of focus, and it continues to expand into additional therapeutic areas to address unmet medical needs.

Ascendis is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg and Berlin, Germany, and in Palo Alto and Redwood City, California.